241 results about "Endogeny" patented technology

The present disclosure relates to a novel fluorogenic dimer compound, useful as a probe for detection of endogenous receptors, in particular G protein-coupled receptors. The present invention provides compositions and kits comprising such compound and methods of labeling a biomolecule, comprising the step of contacting the biomolecule with the compound of the invention.

This document provides novel recombinant polypeptides comprising an endogenous cell protrusion targeting signal peptide and a payload protein, nucleic acid molecules encoding said recombinant polypeptides, pharmaceutical compositions comprising said nucleic acid molecules, and methods of using the same. In some embodiments, the recombinant polypeptide comprises the formula X1-(Y1)a-Z1, wherein X1 is an endogenous signal peptide, Y1 is a peptide linker, and Z1 is a payload protein, wherein a is an integer selected from 0 and 1.

This invention provides a combination of metabolic biomarkers for T-staging assessment of colorectal cancer, comprising four groups of metabolite combinations specifically distinguishing different T stages of colorectal cancer, each group containing 10 endogenous small molecule metabolites. This invention also provides detection methods and applications for the above-mentioned metabolic biomarker combinations. Furthermore, this invention provides a method for T-staging colorectal cancer for non-diagnostic and therapeutic purposes, as well as a combination of metabolic biomarkers related to the evolution of T-staging and tumor invasion depth in colorectal cancer. The advantages of this invention are: by combining iEESI-MS detection with multivariate statistics and machine learning, specific metabolic biomarkers related to T-staging of colorectal cancer are screened, a T-staging discrimination model is constructed, and objective, accurate, and rapid assessment of T-staging of colorectal cancer is achieved, providing molecular support for preoperative individualized treatment.

The application belongs to the technical field of biomedical materials, and discloses a collagen-based double-network porous hydrogel scaffold capable of recruiting endogenous stem cells and a construction method and application thereof. The scaffold takes collagen II (Col-II) and oxidized methyl acrylated hyaluronic acid (AHAMA) as an organic phase, and is constructed into a physical / chemical double-network structure through Schiff base dynamic crosslinking and ultraviolet light-induced methacryl radical polymerization. An air-in-water emulsion template method is used to form a through-porous structure, and 5' aldehyde-modified nucleic acid aptamer Apt19S is anchored in the scaffold network to achieve specific recruitment of endogenous pluripotent stem cells. The scaffold has excellent mechanical properties, a biomimetic extracellular matrix microenvironment and a targeted stem cell recruitment function, can effectively promote the directional differentiation of stem cells into chondrocytes, avoids the immune rejection and ethical issues caused by exogenous stem cell transplantation, and is suitable for the field of articular cartilage defect repair.

This invention provides the application of a Qi-tonifying and blood-nourishing composition in the preparation of a drug for premenstrual syndrome (PMS), relating to the field of pharmaceutical technology. The application of this Qi-tonifying and blood-nourishing composition in the preparation of a drug for treating a specific phenotype of PMS is characterized by an abnormally low abundance of *Isobacterium* spp. and / or a deficiency in endogenous docosahexaenoic acid (DHA) metabolism. The active ingredients of the Qi-tonifying and blood-nourishing composition include pig blood extract, astragalus, and jujube. This invention precisely targets individuals with a specific phenotype of PMS with a low abundance of *Isobacterium* spp. or DHA deficiency, addressing the underlying mechanism of PMS. The application of a composition containing pig blood extract, astragalus, and jujube can target and correct the aforementioned microecological and metabolic imbalances, achieving targeted and precise treatment and significantly improving the specificity of medication.

This invention relates to a method, kit, and application for assessing the cardiotoxicity risk of processed Aconitum carmichaelii products based on NFKB1, PSMB1, and FGR biomarkers, belonging to the field of traditional Chinese medicine processing technology. The invention provides a biomarker specifically any one of the NFKB1, PSMB1, or FGR genes, or any combination thereof. This invention is the first to identify the key causal biomarkers NFKB1, PSMB1, and FGR that cause cardiotoxicity from Aconitum carmichaelii toxic components. A dynamic response model composed of these three genes can accurately quantify the degree of toxicity transformation during Aconitum carmichaelii processing: elevated NFKB1 expression indicates a risk of inflammatory activation, decreased PSMB1 expression reflects the critical point of protein homeostasis collapse, and persistent inhibition of FGR expression indicates the failure of endogenous cardioprotective mechanisms. The predictive model constructed using these three genes can accurately assess the cardiotoxicity of processed Aconitum carmichaelii products and evaluate the Aconitum carmichaelii processing technology.

Provided are methods for modifying endogenous TCR genes to produce iPSC-derived T cells with antigen- and sequence-specific TCRs. Also provided are genetically engineered iPSCs, genetically engineered T cells, genetically engineering CAR-T cells, and methods of using the same.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application discloses a liver-targeted gene editing system based on endogenous promoter hijacking and application, and belongs to the field of biological medicine. The system is composed of an LNP-wrapped modified Cas nuclease mRNA (first component) and a promoter-free viral vector carrying a therapeutic transgene donor (second component). The system uses LNP to realize the transient burst expression of Cas nuclease in the liver, mediates the generation of double-strand breaks at the site of endogenous high-expression genes, induces the site-specific integration of therapeutic transgenes without exogenous promoters, and hijacks the expression driven by endogenous promoters by using the splice acceptor (SA) mechanism. The application solves the risk of carcinogenesis caused by random integration of exogenous strong promoters and the immunotoxicity of long-term expression of nucleases through a "double safety lock" design. Experimental results prove that the system has high editing efficiency, long-term stability and no off-target, and can be used for various liver-derived metabolic diseases such as hemophilia, hypercholesterolemia and the like.

Systems and methods for sensing vibrational absorption induced photothermal effect via a visible light source. A Mid-infrared photothermal probe (MI-PTP, or MIP) approach achieves 10 mM detection sensitivity and sub-micron lateral spatial resolution. Such performance exceeds the diffraction limit of infrared microscopy and allows label-free three-dimensional chemical imaging of live cells and organisms. Distributions of endogenous lipid and exogenous drug inside single cells can be visualized. MIP imaging technology may enable applications from monitoring metabolic activities to high-resolution mapping of drug molecules in living systems, which are beyond the reach of current infrared microscopy.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

The application belongs to the field of medical materials, and particularly relates to a metal core enhanced double-barrier piezoelectric nano system and a preparation method and application thereof. The preparation method comprises the following steps: first, a core-shell structure of'metal@mesoporous titanium dioxide@mesoporous barium titanate' is prepared through a step-by-step reaction, and then the target nanoparticles are obtained through lipid wrapping. The system innovatively constructs a double-barrier structure, can self-trigger active oxygen under a physiological pressure of 4 mmHg, realizes endogenous pressure self-driven treatment of malignant ascites, has the advantages of low pressure, high catalytic efficiency, long-term structural stability and good biocompatibility, solves the problems that existing treatment methods are highly invasive and depend on exogenous stimulation, and provides a new safe and efficient technical scheme for the treatment of malignant ascites.

This invention discloses a polypeptide that inhibits the desimilarization activity of tau protein and its applications, belonging to the field of biomedical technology. The polypeptide of this invention is tau. 438 The peptide is obtained through endogenous tau protein synthesis. The peptide provided by this invention can inhibit tau protein desimulation and increase tau mimicry, exhibiting high specificity and safely and effectively improving cognitive and memory function in AD model mice.

This invention discloses a microRNA-responsive 1,2-dioxane-based chemiluminescent compound, its dual-probe system, kit, synthesis method, and applications. The compound's core is an o-acrylate-substituted phenoxyadamantane-1,2-dioxane, with the phenolic hydroxyl group protected by an azide benzyl group. The two-component probe system constructed based on this compound comprises an azide-modified first probe and a phosphine-modified second probe, each complementary to different segments of the target microRNA. Hybridization brings the two probes closer, triggering a Staudinger reaction to remove the protecting group and activate the chemiluminescent signal. This probe system requires no enzyme amplification or nucleic acid extraction, achieves a detection limit of 1.37 fM, and a signal-to-noise ratio as high as 157-fold. It can be successfully used for real-time imaging of endogenous microRNA-21 in live cells, showing broad application prospects in early tumor screening, auxiliary diagnosis, and prognostic assessment.

The present application relates to a kind of high-efficiency screening methods for risk substances in animal-derived food, comprising the following steps: 1) after the pretreatment of the animal-derived food sample to be tested, non-target detection and analysis are carried out using chromatography-mass spectrometry platform, and original chromatography-mass spectrometry data are obtained;2) by global network optimization, filter food endogenous components, while using quartile range method to remove various background interference, extract suspicious risk substances;Suspected risk substances that meet the conditions of global network optimization and quartile range method filtering at the same time are retained;3) by database search and standard comparison, the structure of suspicious risk substances is annotated and qualified.The present application effectively removes the interference of food endogenous components on risk substance screening, improves the efficiency of non-target screening.On the other hand, it has significant advantages in the screening analysis and efficient locking of unknown risk substances in animal-derived food.The present application has the advantages of high screening accuracy and low false positive rate.

The described system designed to promote the biological attachment of fibrous connective tissue to a bone implant features a bone implant with a scaffold defining a porous attachment surface, a suction port, and a manifold that distributes a negative pressure gradient across the attachment surface. The system also includes an extracorporeal vacuum pump and a percutaneous suction hose connecting the suction port of the implant to the vacuum pump. The implant is placed in the patient's body with connective tissue applied over the attachment surface, and the suction hose is attached and connected to the vacuum pump. The vacuum pump, operating outside the body, creates a negative pressure gradient over an extended period, promoting the growth of slow growing Sharpey's fibres for superior biological integration. A highly vascularised tissue graft, such as a pedicled muscle flap, may be applied adjacent to the avascular tendon to enhance endogenous growth factor migration.

Provided herein is an antisense oligonucleotide (ASO) for use in the prevention or treatment of a disease or a condition associated with ApoB in a subject, wherein the ASO effects site- directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous ApoB gene.

Disclosed herein are multi-specific binding polypeptide molecules (e.g., multi-specific antibodies) that are capable of interacting with TNF-related apoptosis-inducing ligand (TRAIL) receptors and cell-specific antigens. In some embodiments, methods for using the multi-specific binding polypeptides (e.g., multi-specific antibodies) to treat one or more diseases or conditions (e.g., cancer) are also described herein.

A spatial in situ sequencing method, belonging to the field of biology, is proposed. It utilizes an electric field-assisted directed migration of mRNA and in-situ capture with primers on a microarray surface to enrich tissue and release mRNA. In-situ reverse transcription generates covalently fixed cDNA, ensuring high positional stability during multiple rounds of hybridization and imaging. After reverse transcription, tissue is digested to remove tissue, reducing spatial hindrance and background interference, while the cDNA remains at its original coordinates due to covalent anchoring. Combining coding probe hybridization and RCA, single-molecule-level signal amplification and recognition are achieved. Through decoding and single-cell segmentation, transcripts are mapped to their respective cells, constructing a single-cell resolution spatial gene expression map. This method does not rely on multi-round DAPI mapping or other endogenous morphological marker-based multi-cycle image registration methods, making it suitable for high-throughput spatial in situ sequencing and significantly improving robustness and versatility in complex imaging scenarios such as thick tissue sections and low signal-to-noise ratios. It is applicable to high spatial resolution, high-throughput spatial transcriptome research.

The present disclosure provides methods for using antibodies that bind to Factor XI (FXI) for the purpose of preventing or treating clot formation or thrombogenesis after a surgical procedure. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat or prevent clot formation in a subject requiring such treatment, such as, but not limited to, post-surgery.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

The application discloses a method for constructing a CRBN gene humanized mouse model, which comprises replacing a knockout region of a mouse CRBN gene with a knock-in region of a human CRBN gene, so that the CRBN gene humanized mouse model is constructed, and the CRBN gene of the CRBN gene humanized mouse model is subjected to amino acid substitution of S369C, V380E, I391V and E431D. The application replaces a key functional domain of a mouse endogenous CRBN gene with a corresponding sequence of a human CRBN gene, so that the mouse can express a functional human CRBN protein, thereby solving the problem of lack of sensitivity of a wild-type mouse to a CRBN-dependent drug. The model provides an ideal preclinical experimental platform for studying the efficacy, toxicity and mechanism of action of a CRBN-related drug.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

This application relates to the field of biomedical materials and discloses a bio-based functional material that promotes blood circulation and its preparation method. The material is in hydrogel form and is prepared from an active precursor solution, a hydrogel matrix solution, and a functional modifier. The active precursor solution is assembled using a eutectic solvent-mediated process, which breaks the hydrogen bonds within the lignin molecule, causing its conformation to unfold, and constructs coordination catalytic centers with copper and chloride ions. The hydrogel matrix solution is mainly composed of polyvinyl alcohol and water. The preparation method includes high-temperature pre-assembly of the precursor, two-phase mixing, reduction regulation, and freeze-thaw cycle molding. This invention utilizes the microenvironmental regulation effect of the eutectic solvent to lower the electron transfer barrier of copper ions and achieves stable anchoring of copper ions using the lignin framework, solving the problems of easy loss and deactivation of copper catalysts. It features high catalytic efficiency, good stability, and suitable mechanical strength, and can efficiently catalyze the release of nitric oxide from endogenous donors.

This invention discloses the application of lipoic acid analog formulations in the preparation of anti-cardiomyocyte senescence products. The lipoic acid analog DMAE-LA is N-(2-(dimethylamino)ethyl)-5-(1,2-dithiopentane-3-yl)pentanamide, with a concentration of 2-25 μM. DMAE-LA pretreatment effectively reduces intracellular ROS, improves mitochondrial function, inhibits the overexpression of p21 and HMGB1, and restores Lamin B1 levels, thereby alleviating the senescent manifestations of cardiomyocytes. DMAE-LA reduces H₂S oxidative depletion by inhibiting ROS generation and may promote H₂S synthase activity, increasing endogenous H₂S levels and further enhancing cellular antioxidant capacity. In summary, DMAE-LA can significantly inhibit cardiomyocyte senescence through multiple antioxidant mechanisms and organelle function protection, providing a potential intervention strategy for targeting cellular senescence in cardiovascular diseases.

This invention discloses a method for preparing fucoidan from *Sargassum hemifolia* and its application in the preparation of anti-hepatocellular carcinoma drugs. Experimental results show that *Sargassum hemifolia* fucoidan Fb has a strong inhibitory effect on HepG2 hepatocellular carcinoma cells, significantly stronger than the inhibitory effects of *Sargassum henryi* polysaccharide Fh and *Sargassum fusiforme* polysaccharide SFPS on HepG2 hepatocellular carcinoma cells. After treatment of HepG2 hepatocellular carcinoma cells with *Sargassum hemifolia* fucoidan DF1 and DF2, apoptosis is ultimately induced through the interaction and cooperation of exogenous (death receptor pathway) and endogenous (mitochondrial pathway). *Sargassum hemifolia* fucoidan possesses strong antitumor activity and therefore can be used to prepare anti-hepatocellular carcinoma drugs.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

This invention relates to the fields of synthetic biology and metabolic engineering, specifically to a Streptomyces promoter selection marker and its application. The selection marker gene is *Streptomyces lilacinus*. Streptomyces lavendulae Glutamine indigo synthase gene derived from CGMCC 4.1386 idgS This invention screens endogenous promoters of *Streptomyces freundii* using heterologously expressed idgS genes; and constructs a detection system for endogenous promoters of *Streptomyces freundii* using this scheme, which can rapidly detect endogenous promoters of *Streptomyces freundii* and the strength of each promoter.

This invention belongs to the field of biomedical technology, specifically relating to a delivery system for type III collagen mRNA and its applications. The nucleic acid delivery system of this invention includes a delivery carrier and a delivered nucleic acid, wherein the nucleic acid is collagen mRNA, and the delivery carrier includes one or more of modified amino acids, growth factors, and polymeric materials. Through intradermal injection, the delivery system of this invention can be administered to the dermal layer of the skin and enter relevant cells, utilizing endogenous cellular proteins to achieve mRNA transfection, forming natural human type III collagen. This invention avoids the immunogenicity risks and structural inactivation problems associated with exogenous collagen injections, and can efficiently and safely replenish non-regenerative type III collagen in tissues. It can be used for various indications such as treating skin aging, promoting wound healing, reducing scar formation, and improving vascular elasticity.

This invention discloses an endogenous peptide from monkfish with antioxidant and anti-inflammatory activities, its preparation method, and its applications. The endogenous peptide from monkfish includes at least one of HPLK, PRK, VLPN, LGPQ, EVL, and LGYPPQ. The preparation method includes the following steps: monkfish is skinned, the flesh is minced, and then extracted with formic acid solution overnight. After homogenization, the supernatant is collected by centrifugation to obtain a supernatant of the fish meat sample. A Fe3O4@PDA magnetic material solution is added to the supernatant of the fish meat sample, and after shaking incubation and magnetic separation, the Fe3O4@PDA sample is collected. NaCl solution is added to elute the adsorbed endogenous peptides. The eluent is collected, dialyzed to remove salt, and freeze-dried to obtain the endogenous peptide from monkfish. The invention also provides applications of the above-mentioned endogenous peptide from monkfish in the preparation of antioxidants and anti-inflammatory reagents. The advantage is that it possesses antioxidant and anti-inflammatory activities.